Cargando…

Type 1 diabetes and engineering enhanced islet transplantation

The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D) relies on the precise understanding and deciphering of insulin-secreting β-cell biology, as well as the mechanisms responsible for their autoimmune destruction. β-cell or islet transplantation is viewed as a potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeyagaran, Abiramy, Lu, Chuan-en, Zbinden, Aline, Birkenfeld, Andreas L., Brucker, Sara Y., Layland, Shannon L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Publishers, B.V 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531713/
https://www.ncbi.nlm.nih.gov/pubmed/36002043
http://dx.doi.org/10.1016/j.addr.2022.114481
_version_ 1784801959525482496
author Jeyagaran, Abiramy
Lu, Chuan-en
Zbinden, Aline
Birkenfeld, Andreas L.
Brucker, Sara Y.
Layland, Shannon L.
author_facet Jeyagaran, Abiramy
Lu, Chuan-en
Zbinden, Aline
Birkenfeld, Andreas L.
Brucker, Sara Y.
Layland, Shannon L.
author_sort Jeyagaran, Abiramy
collection PubMed
description The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D) relies on the precise understanding and deciphering of insulin-secreting β-cell biology, as well as the mechanisms responsible for their autoimmune destruction. β-cell or islet transplantation is viewed as a potential long-term therapy for the millions of patients with diabetes. To advance the field of insulin-secreting cell transplantation, two main research areas are currently investigated by the scientific community: (1) the identification of the developmental pathways that drive the differentiation of stem cells into insulin-producing cells, providing an inexhaustible source of cells; and (2) transplantation strategies and engineered transplants to provide protection and enhance the functionality of transplanted cells. In this review, we discuss the biology of pancreatic β-cells, pathology of T1D and current state of β-cell differentiation. We give a comprehensive view and discuss the different possibilities to engineer enhanced insulin-secreting cell/islet transplantation from a translational perspective.
format Online
Article
Text
id pubmed-9531713
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Science Publishers, B.V
record_format MEDLINE/PubMed
spelling pubmed-95317132022-10-11 Type 1 diabetes and engineering enhanced islet transplantation Jeyagaran, Abiramy Lu, Chuan-en Zbinden, Aline Birkenfeld, Andreas L. Brucker, Sara Y. Layland, Shannon L. Adv Drug Deliv Rev Article The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D) relies on the precise understanding and deciphering of insulin-secreting β-cell biology, as well as the mechanisms responsible for their autoimmune destruction. β-cell or islet transplantation is viewed as a potential long-term therapy for the millions of patients with diabetes. To advance the field of insulin-secreting cell transplantation, two main research areas are currently investigated by the scientific community: (1) the identification of the developmental pathways that drive the differentiation of stem cells into insulin-producing cells, providing an inexhaustible source of cells; and (2) transplantation strategies and engineered transplants to provide protection and enhance the functionality of transplanted cells. In this review, we discuss the biology of pancreatic β-cells, pathology of T1D and current state of β-cell differentiation. We give a comprehensive view and discuss the different possibilities to engineer enhanced insulin-secreting cell/islet transplantation from a translational perspective. Elsevier Science Publishers, B.V 2022-10 /pmc/articles/PMC9531713/ /pubmed/36002043 http://dx.doi.org/10.1016/j.addr.2022.114481 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Jeyagaran, Abiramy
Lu, Chuan-en
Zbinden, Aline
Birkenfeld, Andreas L.
Brucker, Sara Y.
Layland, Shannon L.
Type 1 diabetes and engineering enhanced islet transplantation
title Type 1 diabetes and engineering enhanced islet transplantation
title_full Type 1 diabetes and engineering enhanced islet transplantation
title_fullStr Type 1 diabetes and engineering enhanced islet transplantation
title_full_unstemmed Type 1 diabetes and engineering enhanced islet transplantation
title_short Type 1 diabetes and engineering enhanced islet transplantation
title_sort type 1 diabetes and engineering enhanced islet transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531713/
https://www.ncbi.nlm.nih.gov/pubmed/36002043
http://dx.doi.org/10.1016/j.addr.2022.114481
work_keys_str_mv AT jeyagaranabiramy type1diabetesandengineeringenhancedislettransplantation
AT luchuanen type1diabetesandengineeringenhancedislettransplantation
AT zbindenaline type1diabetesandengineeringenhancedislettransplantation
AT birkenfeldandreasl type1diabetesandengineeringenhancedislettransplantation
AT bruckersaray type1diabetesandengineeringenhancedislettransplantation
AT laylandshannonl type1diabetesandengineeringenhancedislettransplantation